KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Current Assets: 2011-2024

Historic Current Assets for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Dec 2024 value amounting to $686.1 million.

  • Supernus Pharmaceuticals' Current Assets fell 7.20% to $593.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $593.9 million, marking a year-over-year decrease of 7.20%. This contributed to the annual value of $686.1 million for FY2024, which is 39.13% up from last year.
  • According to the latest figures from FY2024, Supernus Pharmaceuticals' Current Assets is $686.1 million, which was up 39.13% from $493.1 million recorded in FY2023.
  • In the past 5 years, Supernus Pharmaceuticals' Current Assets ranged from a high of $734.2 million in FY2022 and a low of $493.1 million during FY2023.
  • Over the past 3 years, Supernus Pharmaceuticals' median Current Assets value was $686.1 million (recorded in 2024), while the average stood at $637.8 million.
  • In the last 5 years, Supernus Pharmaceuticals' Current Assets slumped by 32.83% in 2023 and then spiked by 39.13% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' Current Assets (Yearly) stood at $630.4 million in 2020, then declined by 4.57% to $601.6 million in 2021, then increased by 22.04% to $734.2 million in 2022, then slumped by 32.83% to $493.1 million in 2023, then soared by 39.13% to $686.1 million in 2024.